[1]BioorganicandMedicinalChemistryLetters,2014,vol.24,p.4455-4459
[2]Patent:WO2005/28469,2005,A1.Locationinpatent:Page/Pagecolumn58
[3]ACSMedicinalChemistryLetters,2013,vol.4,p.742-746
[1]CurrentPatentAssignee:ASTRAZENECAPLC-US2009/286982,2009,A1Locationinpatent:Page/Pagecolumn14-15
[1]CurrentPatentAssignee:ASTRAZENECAPLC-US2009/286982,2009,A1Locationinpatent:Page/Pagecolumn18-19
[2]CurrentPatentAssignee:ASTRAZENECAPLC-WO2010/122340,2010,A2Locationinpatent:Page/Pagecolumn30-31
[1]Goundry,WilliamR.F.;Boardman,Kay;Cunningham,Oliver;Evans,Matthew;Jones,MartinF.;Millard,Kirsty;Rozada-Sanchez,Raquel;Sawyer,Yvonne;Siedlecki,Paul;Whitlock,Brian[OrganicProcessResearchandDevelopment,2017,vol.21,#3,p.336-345]
[2]CurrentPatentAssignee:ASTRAZENECAPLC-US2009/286982,2009,A1Locationinpatent:Page/Pagecolumn15-16
[3]CurrentPatentAssignee:ASTRAZENECAPLC-WO2010/122340,2010,A2Locationinpatent:Page/Pagecolumn17-18;21
[1]CurrentPatentAssignee:ASTRAZENECAPLC-WO2010/122340,2010,A2Locationinpatent:Page/Pagecolumn21-24
[2]Goundry,WilliamR.F.;Boardman,Kay;Cunningham,Oliver;Evans,Matthew;Jones,MartinF.;Millard,Kirsty;Rozada-Sanchez,Raquel;Sawyer,Yvonne;Siedlecki,Paul;Whitlock,Brian[OrganicProcessResearchandDevelopment,2017,vol.21,#3,p.336-345]
Title: Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
Journal: ACS medicinal chemistry letters 20130808
Title: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100215
Title: Hickinson DM, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res. 2010 Feb 15;16(4):1159-69.
Title: Mu Z, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res. 2014 May 30;33:47.
Title: Barlaam B, et al. Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Med Chem Lett. 2013 May 31;4(8):742-6.
Title: Wang R, et al. Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion. Mol Cancer Res. 2018 Aug 21. pii: molcanres.0341.2018.
